C2i Genomics, a New York, NY-based cancer intelligence company, raised $100m in financing.
The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. The financing was executed as a convertible note with two tranches of $50m, called by the company with additional participation from The Mark Foundation for Cancer Research, Silver Lake, Alexandria Real Estate, Gordon Asset Management, and LionBird.
The company intends to use the funds to accelerate clinical development and commercialization of its C2-Intelligence Platform and to deepen its partnerships with pharmaceutical companies.
Led by Asaf Zviran, co-founder and CEO, C2i provides a cloud-based cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease. With the platform, physicians can spot trace amounts of persistent or recurrent cancer much earlier, at far lower levels, to inform treatment decisions. The technology can be deployed locally to provide actionable insights into the progression of a patient’s cancer as rapidly as in one week, enabling informed and timely treatment decisions.
The C2i Intelligence Platform is GDPR and HIPAA compliant and is currently being used for both clinical and drug development research in multiple locations, including the National Cancer Center of Singapore (NCCS), Aarhus University Hospital, NYU Langone Health, Lausanne University Hospital (CHUV), and others.
The company also has R&D center in Haifa, Israel and a sequencing lab in Cambridge, MA.